🔗 Share this article

A daily slimming tablet could help people reduce their weight by up to 20%, as per a trial that could open doors for millions more people to shed pounds.

How the Drug Functions

This medication, known as orforglipron, focuses on the identical GLP-1 receptors as weight loss shots like Mounjaro and Wegovy. In a trial of over 3,000 adults, one in five people who took the once-a-day pill for more than a year lost 20% or more of their total weight.

Weight loss injections have been revolutionary, but pill versions represent a major breakthrough since they are easier to keep, share and administer, and are also projected to be cheaper, providing fresh hope for many people attempting to reduce weight.

Orforglipron is a GLP-1 stimulant, a class of medication that helps lowering glucose levels, slows the breakdown of food and can curb hunger.

Trial Findings and Accessibility

Slimming results seen in participants taking the pill is not as stark as that in users taking injectable alternatives, but specialists think the oral form will be easier to obtain and user-friendly than injections.

Orforglipron is not yet approved by the US Food and Drug Administration or regulators in other countries. Developers stated it expects substantial demand when the oral treatment is launched.

During the trial, the 3,127 participants were divided into cohorts taking orforglipron tablets of varying strengths, whereas some took a placebo, for 72 weeks.

Each of the patients had obesity, meaning they had a body mass index reading of 30 or higher, but they did not have diabetes. Participants from several countries were involved in the research.

Key Outcomes

Researchers found that after 72 weeks people on the lowest dose lost an mean of 7.5% of their weight. Those on the maximum amount shed an average of over 11% of their weight.

Among patients taking the highest doses, more than half had a decrease of at least 10% of weight, over a third had a reduction of 15% or greater, and 18.4% had a drop of 20% or higher.

The team reported additional health metrics additionally improved in participants taking the medication, such as better BP, a reduced waist circumference and a reduction in bad cholesterol.

The most common adverse reactions were stomach-related, which were described as manageable.

“Among participants diagnosed with obesity, 72-week treatment with orforglipron resulted in significantly greater decreases in body weight than inactive treatment,” the authors wrote.

Potential Benefits

Health leaders have praised weight loss drugs as game-changing. However injections involve additional work for health services, so tablet forms might help many additional people trying to lose weight.

Additional research shows weight loss jabs may be effective on children as young as six who have obesity or have diabetes. However, stomach problems were “significantly more common” in children using the drugs.

Experts emphasized that longer follow-up durations in upcoming trials and more practical analysis were crucial to determine the lasting impacts.”